Ranibizumab for the treatment of degenerative ocular conditions

References

• ApteRSScheufeleTABlomquistPHEtiology of blindness in an urban community hospital settingOphthalmology2001108469369611297485
   PubMed Web of Science ®Google Scholar
• HollowayTBVerhoeffFHDisc-like degeneration of the macula with microscopic report concerning a tumor-like mass in the macular regionTrans Am Ophthalmol Soc19282620622816692794
   PubMedGoogle Scholar
• IvandicBTIvandicTLow-level laser therapy improves vision in patients with age-related macular degenerationPhotomed Laser Surg200826324124518588438
   PubMed Web of Science ®Google Scholar
• DoDVAntiangiogenic approaches to age-related macular degeneration in the futureOphthalmology200911610 SupplS24S2619800536
   PubMed Web of Science ®Google Scholar
• JoussenAMBornfeldNThe treatment of wet age-related macular degenerationDtsch Arztebl Int20091061831231719547647
   PubMed Web of Science ®Google Scholar
• GragoudasESAdamisAPCunninghamETJrFeinsodMGuyerDRVEGF Inhibition Study in Ocular Neovascularization Clinical Trial GroupPegaptanib for neovascular age-related macular degenerationN Engl J Med2004351272805281615625332
   PubMed Web of Science ®Google Scholar
• ChakravarthyUWongTYFletcherAClinical risk factors for age-related macular degeneration: a systematic review and meta-analysisBMC Ophthalmol2010103121144031
   PubMed Web of Science ®Google Scholar
• ClemonsTEMiltonRCKleinRSeddonJMFerrisFL3rdAge-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19Ophthalmology2005112453353915808240
   PubMed Web of Science ®Google Scholar
• EdwardsAORitterR3rdAbelKJManningAPanhuysenCFarrerLAComplement factor H polymorphism and age-related macular degenerationScience2005308572042142415761121
   PubMed Web of Science ®Google Scholar
• KabasawaSMoriKHorie-InoueKAssociations of cigarette smoking but not serum fatty acids with age-related macular degeneration in a Japanese populationOphthalmology201111861082108821514959
   PubMed Web of Science ®Google Scholar
• MunchICLinnebergALarsenMPrecursors of age-related macular degeneration: associations with physical activity, obesity, and serum lipids in the inter99 eye studyInvest Ophthalmol Vis Sci20135463932394023652489
   PubMed Web of Science ®Google Scholar
• GoldBMerriamJEZernantJVariation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degenerationNat Genet200638445846216518403
   PubMed Web of Science ®Google Scholar
• RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci20034473186319312824270
   PubMed Web of Science ®Google Scholar
• YannuzziLASorensonJSpaideRFLipsonBIdiopathic polypoidal choroidal vasculopathy (IPCV)Retina1990101181693009
   PubMed Web of Science ®Google Scholar
• KleinerRCBruckerAJJohnstonRLThe posterior uveal bleeding syndromeRetina19901019172343198
   PubMed Web of Science ®Google Scholar
• SternRMZakovZNZegarraHGutmanFAMultiple recurrent sero-sanguineous retinal pigment epithelial detachments in black womenAm J Ophthalmol198510045605692413762
   PubMed Web of Science ®Google Scholar
• YannuzziLAWongDWSforzoliniBSPolypoidal choroidal vasculopathy and neovascularized age-related macular degenerationArch Ophthalmol1999117111503151010565519
   PubMedGoogle Scholar
• LafautBAAisenbreySVan den BroeckeCBartz-SchmidtKUHeimannKPolypoidal choroidal vasculopathy pattern in age-related macular degeneration: a clinicopathologic correlationRetina200020665065411131419
   PubMed Web of Science ®Google Scholar
• SakuradaYYoneyamaSImasawaMIijimaHSystemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degenerationRetina201333484184523400077
   PubMed Web of Science ®Google Scholar
• HiramiYTsujikawaAOtaniAHemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathyRetina200727333534117460589
   PubMed Web of Science ®Google Scholar
• KikuchiMNakamuraMIshikawaKElevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degenerationOphthalmology200711491722172717400294
   PubMed Web of Science ®Google Scholar
• CackettPYeoICheungCMRelationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese personsOphthalmology2011118584685221146223
   PubMed Web of Science ®Google Scholar
• CackettPWongDYeoIA classification system for polypoidal choroidal vasculopathyRetina200929218719118827731
   PubMed Web of Science ®Google Scholar
• TsujikawaAOotoSYamashiroKTamuraHOtaniAYoshimuraNTreatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumabJpn J Ophthalmol201054431031920700799
   PubMed Web of Science ®Google Scholar
• StangosANGandhiJSNair-SahniJHeimannHPournarasCJHardingSPPolypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumabAm J Ophthalmol2010150566667320719300
   PubMed Web of Science ®Google Scholar
• NakashizukaHMitsumataMOkisakaSClinicopathologic findings in polypoidal choroidal vasculopathyInvest Ophthalmol Vis Sci200849114729473718586873
   PubMed Web of Science ®Google Scholar
• ChoMBarbazettoIAFreundKBRefractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathyAm J Ophthalmol200914817078.e119403115
   PubMed Web of Science ®Google Scholar
• CohenSYLarocheALeguenYSoubraneGCoscasGJEtiology of choroidal neovascularization in young patientsOphthalmology19961038124112448764794
   PubMed Web of Science ®Google Scholar
• SawSMA synopsis of the prevalence rates and environmental risk factors for myopiaClin Exp Optom200386528929414558850
   PubMedGoogle Scholar
• KempenJHMitchellPLeeKEThe prevalence of refractive errors among adults in the United States, Western Europe, and AustraliaArch Ophthalmol2004122449550515078666
   PubMedGoogle Scholar
• JacobiFKZrennerEBroghammerMPuschCMA genetic perspective on myopiaCell Mol Life Sci2005627–880080815868405
   PubMed Web of Science ®Google Scholar
• HayashiKOhno-MatsuiKShimadaNLong-term pattern of progression of myopic maculopathy: a natural history studyOphthalmology20101178159516111611.e1e420207005
   PubMed Web of Science ®Google Scholar
• YoshidaTOhno-MatsuiKYasuzumiKMyopic choroidal neovascularization: a 10-year follow-upOphthalmology200311071297130512867382
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSTatlipinarSDoDVAndenEVCampochiaroPABevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBr J Ophthalmol200589101368137016170134
   PubMed Web of Science ®Google Scholar
• IkunoYSayanagiKSogaKIntravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year resultsAm J Ophthalmol2009147194100.e118774550
   PubMed Web of Science ®Google Scholar
• NakanishiHTsujikawaAYodoiYPrognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularizationEye (Lond)201125337538121252956
   PubMed Web of Science ®Google Scholar
• HefnerLRieseJGerdingHThree years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopiaKlin Monbl Augenheilkd2013230440140423629791
   PubMed Web of Science ®Google Scholar
• Romero-ArocaPCurrent status in diabetic macular edema treatmentsWorld J Diabetes20134516516924147200
   PubMedGoogle Scholar
• BresnickGHDiabetic macular edema. A reviewOphthalmology19869379899973531959
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusThe Diabetes Control and Complications Trial Research GroupN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edemaEarly Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research groupArch Ophthalmol198510312179618062866759
   PubMedGoogle Scholar
• BrownleeMBiochemistry and molecular cell biology of diabetic complicationsNature2001414686581382011742414
   PubMed Web of Science ®Google Scholar
• MassinPBandelloFGarwegJGSafety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II studyDiabetes Care201033112399240520980427
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloFSchmidt-ErfurthURESTORE study groupThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology2011118461562521459215
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMHeierJSREAD-2 Study GroupPrimary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) studyOphthalmology20091161121752181.e119700194
   PubMed Web of Science ®Google Scholar
• ParodiMBBandelloFBranch retinal vein occlusion: classification and treatmentOphthalmologica2009223529830519372724
   PubMed Web of Science ®Google Scholar
• HayrehSSZimmermanMBPodhajskyPIncidence of various types of retinal vein occlusion and their recurrence and demographic characteristicsAm J Ophthalmol199411744294418154523
   PubMed Web of Science ®Google Scholar
• WongTYScottIUClinical practice. Retinal-vein occlusionN Engl J Med2010363222135214421105795
   PubMed Web of Science ®Google Scholar
• MacdonaldDThe ABCs of RVO: a review of retinal venous occlusionClin Exp Optom Epub20131120
   Web of Science ®Google Scholar
• Argon laser photocoagulation for macular edema in branch vein occlusionThe Branch Vein Occlusion Study GroupAm J Ophthalmol19849832712826383055
   PubMed Web of Science ®Google Scholar
• ShillingJSJonesCARetinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedemaBr J Ophthalmol19846831961986365157
   PubMed Web of Science ®Google Scholar
• Natural history and clinical management of central retinal vein occlusionThe Central Vein Occlusion Study GroupArch Ophthalmol199711544864919109757
   PubMedGoogle Scholar
• JonasJBKreissigIDegenringRFIntravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusionGraefes Arch Clin Exp Ophthalmol2002240978278312271378
   PubMed Web of Science ®Google Scholar
• JainNStinnettSSJaffeGJProspective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month resultsOphthalmology2012119113213721924503
   PubMed Web of Science ®Google Scholar
• BrownDMCampochiaroPASinghRPCRUISE InvestigatorsRanibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology2010117611241133.e120381871
   PubMed Web of Science ®Google Scholar
• CampochiaroPAHeierJSFeinerLRanibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology2010117611021112.e120398941
   PubMed Web of Science ®Google Scholar
• HamelCRetinitis pigmentosaOrphanet J Rare Dis200614017032466
   PubMed Web of Science ®Google Scholar
• AdlerRMechanisms of photoreceptor death in retinal degenerations. From the cell biology of the 1990s to the ophthalmology of the 21st century?Arch Ophthalmol1996114179838540855
   PubMedGoogle Scholar
• ChongNHBirdACManagement of inherited outer retinal dystrophies: present and futureBr J Ophthalmol199983112012210209449
   PubMed Web of Science ®Google Scholar
• Mauget-FaÿsseMCornutPLQuaranta El-MaftouhiMLeysAPolypoidal choroidal vasculopathy in tilted disk syndrome and high myopia with staphylomaAm J Ophthalmol2006142697097517046703
   PubMed Web of Science ®Google Scholar
• LanghamMEKramerTDecreased choroidal blood flow associated with retinitis pigmentosaEye (Lond)19904Pt 23743812379647
   PubMed Web of Science ®Google Scholar
• ShintaniKShechtmanDLGurwoodASReview and update: current treatment trends for patients with retinitis pigmentosaOptometry200980738440119545852
   PubMedGoogle Scholar
• HajaliMFishmanGAAndersonRJThe prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomographyBr J Ophthalmol20089281065106818653601
   PubMed Web of Science ®Google Scholar
• GroverSApushkinMAFishmanGATopical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosaAm J Ophthalmol2006141585085816546110
   PubMed Web of Science ®Google Scholar
• SalomDDiaz-LlopisMGarcía-DelpechSIntravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosaJ Ocul Pharmacol Ther201026553153220925582
   PubMed Web of Science ®Google Scholar
• FolkmanJShingYAngiogenesisJ Biol Chem19922671610931109341375931
   PubMed Web of Science ®Google Scholar
• YancopoulosGDDavisSGaleNWRudgeJSWiegandSJHolashJVascular-specific growth factors and blood vessel formationNature2000407680124224811001067
   PubMed Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun198916128518582735925
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
   PubMed Web of Science ®Google Scholar
• XuLLuTTuomiLPharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approachInvest Ophthalmol Vis Sci20135431616162423361508
   PubMed Web of Science ®Google Scholar
• WagnerJGPharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equationJ Pharm Sci19837278388426887002
   PubMed Web of Science ®Google Scholar
• WagnerJGNelsonEKinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drugJ Pharm Sci1964531392140314253604
   PubMed Web of Science ®Google Scholar
• LoboEDHansenRJBalthasarJPAntibody pharmacokinetics and pharmacodynamicsJ Pharm Sci200493112645266815389672
   PubMed Web of Science ®Google Scholar
• BlickSKKeatingGMWagstaffAJRanibizumabDrugs200767811991206 discussion 1207–120917521219
   PubMed Web of Science ®Google Scholar
• HeierJSAntoszykANPavanPRRanibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose studyOphthalmology20061134633.e631e63416483659
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTANCHOR Study GroupRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology200911615765.e519118696
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• LloydRHarrisJWadhwaSChambersWFood and Drug Administration approval process for ophthalmic drugs in the USCurr Opin Ophthalmol200819319019418408492
   PubMed Web of Science ®Google Scholar
• KrispelCRodriguesMXinXSodhiARanibizumab in diabetic macular edemaWorld J Diabetes20134631031824379922
   PubMedGoogle Scholar
• BelavicJMDrug updates and approvals: 2012 in reviewNurse Pract20133822442 quiz 42–2323295643
   PubMedGoogle Scholar
• GaudreaultJFeiDBeyerJCPharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbitsRetina20072791260126618046235
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci200546272673315671306
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis)Ophthalmology2007114122179218218054637
   PubMed Web of Science ®Google Scholar
• ChongVBiological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factorsOphthalmologica2012227Suppl 121022517120
   PubMed Web of Science ®Google Scholar
• KrohneTULiuZHolzFGMeyerCHIntraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humansAm J Ophthalmol20121544682686.e222818800
   PubMed Web of Science ®Google Scholar
• StewartMWClinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on afliberceptClin Ophthalmol201261175118622973088
   PubMedGoogle Scholar
• ForooghianFCukrasCMeyerleCBChewEYWongWTTachyphylaxis after intravitreal bevacizumab for exudative age-related macular degenerationRetina200929672373119516114
   PubMed Web of Science ®Google Scholar
• MuetherPSHoersterRHermannMMKirchhofBFauserSLong-term effects of ranibizumab treatment delay in neovascular age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2013251245345822573410
   PubMed Web of Science ®Google Scholar
• AbrahamPYueHWilsonLRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2Am J Ophthalmol20101503315324.e120598667
   PubMed Web of Science ®Google Scholar
• MenghiniMKloeckener-GruissemBFleischhauerJImpact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degenerationPLoS One201277e4201422848690
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUEldemBGuymerREXCITE Study GroupEfficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE studyOphthalmology2011118583183921146229
   PubMed Web of Science ®Google Scholar
• SingerMAAwhCCSaddaSHORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degenerationOphthalmology201211961175118322306121
   PubMed Web of Science ®Google Scholar
• SilvaRAxer-SiegelREldemBSECURE Study GroupThe SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degenerationOphthalmology2013120113013923021093
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol2007143456658317386270
   PubMed Web of Science ®Google Scholar
• GuptaOPShienbaumGPatelAHFecarottaCKaiserRSRegilloCDA treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impactOphthalmology2010117112134214020591490
   PubMed Web of Science ®Google Scholar
• LalaCFrammeCWolf-SchnurrbuschUEWolfSThree-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degenerationActa Ophthalmol201391652653022697404
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGFineSLRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• NeriPMariottiCArapiIBambiniEGiovanniniAAnti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?Curr Med Res Opin201228339540022283373
   PubMed Web of Science ®Google Scholar
• FribergTRTolentinoMLEVEL Study GroupWeberPPatelSCampbellSGoldbaumMPegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL studyBr J Ophthalmol201094121611161720472746
   PubMed Web of Science ®Google Scholar
• InoueMArakawaAYamaneSKadonosonoKLong-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathyEye (Lond)201327910131020 quiz 102123970023
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar
• BrownDMNguyenQDMarcusDMRIDE and RISE Research GroupLong-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDEOphthalmology2013120102013202223706949
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDKhwajaAAREAD-2 Study GroupRanibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatmentJAMA Ophthalmol2013131213914523544200
   PubMed Web of Science ®Google Scholar
• ChannaRSophieRKhwajaAAREAD-2 Study GroupFactors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumabEye (Lond)201428326927824263379
   PubMed Web of Science ®Google Scholar
• CampochiaroPASophieRPearlmanJRETAIN Study GroupLong-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN studyOphthalmology2014121120921924112944
   PubMed Web of Science ®Google Scholar
• KorobelnikJFHolzFGRoiderJGALILEO Study GroupIntravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO studyOphthalmology2014121120220824084497
   PubMed Web of Science ®Google Scholar
• IaconoPParodiMBPapayannisAKontadakisSShethSBandelloFIntravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case seriesRetina20113191841184721775926
   PubMed Web of Science ®Google Scholar
• LaiTYLukFOLeeGKLamDSLong-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularizationEye (Lond)20122671004101122595908
   PubMed Web of Science ®Google Scholar
• YangHSKimJGKimJTJoeSGPrognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumabAm J Ophthalmol2013156612011210.e224075429
   PubMed Web of Science ®Google Scholar
• PanosGDGatzioufasZPetropoulosIKDardabounisDThumannGHafeziFEffect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degenerationDrug Des Devel Ther20137565569
   PubMed Web of Science ®Google Scholar
• InoueMArakawaAYamaneSKadonosonoKVariable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathyRetina201333599099723446653
   PubMed Web of Science ®Google Scholar
• ErolMKOzdemirOCobanDTCeranBBBulutMRanibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuitySemin Ophthalmol201429210811324409939
   PubMed Web of Science ®Google Scholar
• DardabounisDAlvanosEGatzioufasZPanosGDIntravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndromeBMJ Case Rep20137172013bcr2013009572
   Google Scholar
• PetrouPGeorgalasIMarkomichelakisNVergadosIGianakakiERouvasAResolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularizationTher Clin Risk Manag2013939139424204154
   PubMed Web of Science ®Google Scholar
• CastellanosMASchwartzSGarcia-AguirreGQuiroz-MercadoHShort-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurityBr J Ophthalmol201397781681923221964
   PubMed Web of Science ®Google Scholar
• UetaTYanagiYTamakiYYamaguchiTCerebrovascular accidents in ranibizumabOphthalmology2009116236219187826
   PubMed Web of Science ®Google Scholar
• BresslerNMBoyerDSWilliamsDFCerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trialsRetina20123291821182823011184
   PubMed Web of Science ®Google Scholar
• KempAPreenDBMorletNMyocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population studyRetina201333592092723492942
   PubMed Web of Science ®Google Scholar
• FongAHLaiTYLong-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edemaClin Interv Aging2013846748323766636
   PubMed Web of Science ®Google Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
   PubMed Web of Science ®Google Scholar
• HolzFGAmoakuWDonateJSUSTAIN Study GroupSafety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN studyOphthalmology2011118466367121459217
   PubMed Web of Science ®Google Scholar
• BoyerDSHeierJSBrownDMFrancomSFIanchulevTRubioRGA Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degenerationOphthalmology200911691731173919643495
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthULangGEHolzFGRESTORE Extension Study GroupThree-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension studyOphthalmology201412151045105324491642
   PubMed Web of Science ®Google Scholar
• VarmaRBresslerNMSuñerIBRAVO and CRUISE Study GroupsImproved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trialsOphthalmology2012119102108211822817833
   PubMed Web of Science ®Google Scholar
• FingerRPWiedemannPBlumhagenFPohlKHolzFGTreatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in GermanyActa Ophthalmol201391654054623171290
   PubMed Web of Science ®Google Scholar
• FrennessonCNilssonULPeeboBBNilssonSESignificant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degenerationActa Ophthalmol201088442042519678811
   PubMed Web of Science ®Google Scholar
• RungLLövestam-AdrianMThree-year follow-up of visual outcome and quality of life in patients with age-related macular degenerationClin Ophthalmol2013739540123467557
   PubMedGoogle Scholar
• RakicJMLeysABriéHReal-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS studyClin Ophthalmol201371849185824092964
   PubMedGoogle Scholar
• HolzFGBandelloFGilliesMLUMINOUS Steering CommitteeSafety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programmeBr J Ophthalmol20139791161116723850682
   PubMed Web of Science ®Google Scholar
• FerrariGDastjerdiMHOkanoboATopical ranibizumab as a treatment of corneal neovascularizationCornea201332799299723407316
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol200914814358.e119376495
   PubMed Web of Science ®Google Scholar